MicroRNA as therapeutics for age-related macular degeneration

Riccardo Natoli*, Nilisha Fernando

*Corresponding author for this work

    Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

    22 Citations (Scopus)

    Abstract

    MicroRNA (miRNA) are a class of endogenously expressed small non-coding RNA molecules that function by repressing or silencing post-transcriptional gene expression. While miRNAs were only identified in humans as recently as the turn of this century, some miRNA-based agents are already in Phase 2 clinical trials (Christopher et al. 2016). This rapid progress from initial discovery to drug development reflects the effectiveness of miRNAs as therapeutic targets. Further, their use as therapeutic agents in the treatment of diseases such as Alzheimer’s disease (Wang et al. 2014) supports their use in other neurodegenerative diseases, such as Age-Related Macular Degeneration (AMD). However, despite ∼300 miRNAs reportedly expressed in the human retina (Xu 2009), relatively little research has been conducted into the therapeutic potential of miRNAs for the treatment of AMD. This review will investigate the use of miRNAs as therapeutic and diagnostic molecules for AMD.

    Original languageEnglish
    Title of host publicationAdvances in Experimental Medicine and Biology
    PublisherSpringer New York LLC
    Pages37-43
    Number of pages7
    DOIs
    Publication statusPublished - 2018

    Publication series

    NameAdvances in Experimental Medicine and Biology
    Volume1074
    ISSN (Print)0065-2598
    ISSN (Electronic)2214-8019

    Fingerprint

    Dive into the research topics of 'MicroRNA as therapeutics for age-related macular degeneration'. Together they form a unique fingerprint.

    Cite this